CLINICAL_TRIALS
trial_result
· 2021-07-28
Clinical Trial Update: Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) [Phase 2]
Summary
Phase 2 trial update on OPK-88004 doses in men with Benign Prostatic Hyperplasia; study terminated with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: OPKO Health, Inc. | Conditions: Benign Prostatic Hyperplasia | Phase 2 | Status: TERMINATED | Results posted: 2021-07-28